Research Analysts’ Recent Ratings Changes for CryoPort (CYRX)

Several brokerages have updated their recommendations and price targets on shares of CryoPort (NASDAQ: CYRX) in the last few weeks:

• 5/20/2026 – CryoPort had its price target raised by KeyCorp from $15.00 to $17.00. They now have an “overweight” rating on the stock.
• 5/11/2026 – CryoPort was upgraded by Wall Street Zen from “sell” to “hold”.
• 5/6/2026 – CryoPort was upgraded by Weiss Ratings from “sell (d+)” to “hold (c-)”.
• 5/5/2026 – CryoPort had its price target raised by Guggenheim from $11.00 to $12.00. They now have a “buy” rating on the stock.
• 5/5/2026 – CryoPort had its price target raised by BTIG Research from $15.00 to $17.00. They now have a “buy” rating on the stock.
• 5/5/2026 – CryoPort had its price target raised by Needham & Company LLC from $13.00 to $15.00. They now have a “buy” rating on the stock.
• 5/3/2026 – CryoPort was downgraded by Wall Street Zen from “hold” to “sell”.
• 4/25/2026 – CryoPort was upgraded by Wall Street Zen from “sell” to “hold”.
• 3/30/2026 – CryoPort is now covered by Craig Hallum. They set a “buy” rating and a $15.00 price target on the stock.
• 3/27/2026 – CryoPort had its “sell (d+)” rating reaffirmed by Weiss Ratings.

Insiders Place Their Bets

In related news, CFO Robert Stefanovich sold 38,700 shares of the company’s stock in a transaction that occurred on Thursday, March 12th. The shares were sold at an average price of $7.76, for a total value of $300,312.00. Following the completion of the sale, the chief financial officer owned 255,701 shares in the company, valued at approximately $1,984,239.76. This represents a 13.15% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Mark W. Sawicki sold 3,235 shares of the company’s stock in a transaction on Monday, March 16th. The shares were sold at an average price of $8.00, for a total value of $25,880.00. Following the transaction, the insider directly owned 103,697 shares in the company, valued at $829,576. The trade was a 3.03% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 59,939 shares of company stock worth $471,183 over the last ninety days. 10.00% of the stock is currently owned by company insiders.

Get CryoPort Inc alerts:

CryoPort, Inc (NASDAQ: CYRX) is a global provider of temperature-controlled logistics solutions for the life sciences industry. The company specializes in cryogenic shipping for critical biological materials, supporting the development, clinical testing and commercialization of cell and gene therapies, biologics, vaccines and reproductive medicine. By offering end-to-end supply chain management, CryoPort helps ensure the integrity and viability of temperature-sensitive products from point of origin to destination.

CryoPort’s product portfolio includes proprietary cryogenic dry shippers, advanced active and passive thermal packaging, and real-time data monitoring platforms.

See Also

• Five stocks we like better than CryoPort
• Meta Platforms 10% Layoff Raises a Bigger Question About AI Spending
• As Small-Cap Outperformance Continues, These 2 ETFs Provide Exposure
• Silicon Shake-Up: The AI Trade Is Moving Beyond NVIDIA
• The Silver Lining of Last Week’s Hims & Hers Earnings Miss

Receive News & Ratings for CryoPort Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CryoPort Inc and related companies with MarketBeat.com's FREE daily email newsletter.